CN102872004B - Application of the naringenin in treatment pneumonia medicine is prepared - Google Patents
Application of the naringenin in treatment pneumonia medicine is prepared Download PDFInfo
- Publication number
- CN102872004B CN102872004B CN201210231492.6A CN201210231492A CN102872004B CN 102872004 B CN102872004 B CN 102872004B CN 201210231492 A CN201210231492 A CN 201210231492A CN 102872004 B CN102872004 B CN 102872004B
- Authority
- CN
- China
- Prior art keywords
- naringenin
- aureus
- forms
- application
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FTVWIRXFELQLPI-UHFFFAOYSA-N Oc1ccc(C(CC2=O)Oc3c2c(O)cc(O)c3)cc1 Chemical compound Oc1ccc(C(CC2=O)Oc3c2c(O)cc(O)c3)cc1 FTVWIRXFELQLPI-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to application of the naringenin in treatment pneumonia medicine is prepared, the protection test and mouse S. aureus L-forms pulmonary inflammation model damaged by rabbit erythrocyte hemolytic test, pulmonary epithelial cells (A549) confirms that it treats S. aureus L-forms infection effect.Contrast uses antibiotic therapy, is had using naringenin and had no drug resistance, the characteristics of cure rate is high.
Description
Technical field
The present invention relates to application of the naringenin in treatment pneumonia medicine is prepared, belong to field of medicaments.
First, background technology
Naringenin (naringenin, Nar, 4,5,7 one tri hydroxy flavanones) is one extracted from Citrus paradisi Macfadyen
Monomer is planted, belongs to flavone compound, it is widely present in lemon, grape juice, orange etc., it is free with stronger removing
Base, anti-oxidant, anti-inflammatory, antiatherosclerosis, anti-fibrosis, cytoprotection, and antibacterial, anti-inflammatory, antitumor etc. are more
Pharmacological action is planted, but at present not yet as medicinal application in clinic.
Bacterial pneumonia be by streptococcus pneumonia (i.e. pneumococcus), staphylococcus aureus, α-hemolytic streptococcus,
Caused by the infection such as bacillus canalis capsulatus, haemophilus influenzae, pseudomonas aeruginosa, bacteria escherichia coli, Pseudomonas aeruginosa
Disease.In recent years, drug resistance of Staphylococcus aureus is increasingly serious, especially methicillin-resistant staphylococcus aureus
(MRSA), there is drug resistance to most of antibiotic.Clinically by the pneumonia incidence of disease of infection of staphylococcus aureus and death
Rate is still very high, and conventional antibiotic is also gradually being reduced in pneumonia effect caused by treatment drug-resistant S. aureus.Cause
This, clinically infection of staphylococcus aureus may face the situation pasted medical help, search out effective novel antibacterial
Medicine turns into exigence.Present invention research is started with from the Major Virulence Factors α hemolysin of staphylococcus aureus, it was demonstrated that
Naringenin is caused by suppressing α hemolysin secretion so as to treat bacterial pneumonia, especially drug-resistant S. aureus
Pneumonia there is preferable therapeutic effect.
2nd, the content of the invention
The molecular structure of naringenin is as follows：
Protection test and mouse gold that the present invention is damaged by rabbit erythrocyte hemolytic test, human squamous lung cancer (A549)
Portugal's bacterium pulmonary inflammation model confirms that it treats S. aureus L-forms infection effect.
3rd, embodiment
1. hemolytic test
Staphylococcus aureus is cultivatedAgain with after the naringenin co-incubation of various concentrations to logarithmic growth
Phase, harvest bacterium solution centrifuging and taking supernatant.Different pharmaceutical concentration culture supernatant is mixed with the rabbit off fiber red blood cell of dilution respectively, in
37 DEG C are incubated 10-20 minutes altogether.The light absorption value of centrifugal measurement supernatant.
Add percent hemolysis such as table 1 below after the naringenin of various concentrations：
Table 1.ATCC 29213, ATCC 10832,8325-4 and BAA-1717 are not handling and added the shaddock of various concentrations
The supernatant haemocylolysis of Pi Su culture
aThe S. aureus culture supernatant of medicine untreated fish group is set as to the haemocylolysis of rabbit erythrocyte
100% haemolysis：None is expressed as observing haemocylolysis；
Each drug-treated group carries out t check analyses otherness with untreated fish group, and (* represents significant difference P ＜ 0.05；* is represented
Difference is extremely notable).
2. the protection test of human squamous lung cancer (A549) damage
S. aureus L-forms NCTC 8325-4 cultivated in TSB culture mediums to5ml bacterial cultures is taken, centrifugation is simultaneously
It is resuspended in 10ml F12K culture mediums.A549 cells are used containing 10% hyclone F12K cultures, with 1.5 × 101Individual cells/well
It is laid in 96 orifice plates, 37 DEG C, 5%CO2Culture 24 hours.After cell attachment, 100 μ l S. aureus L-forms suspensions are added, and add difference
The naringenin of concentration, is placed in cell culture incubator in 37 DEG C, 5%CO2Co-culture 8h.Add live (greed)/dead (red)
Reagent, after the state that A549 cells are observed under laser confocal microscope (LSCM), the aobvious green of living cells, dead cell shows red
Color.
As a result show, naringenin can protect human squamous lung cancer (A549) damage that S. aureus L-forms alpha hemolysin is mediated, should
Dose dependent is presented in effect.
3. the experimental therapeutic research of mouse S. aureus L-forms pneumonia
3.1 mouse S. aureus L-forms pulmonary inflammation models
C57BL/6J mouse (male, 18-22g) are after etherization, μ l S. aureus L-forms suspensions (the S. aureus L-forms 8325- of collunarium 30
4), mouse lies low until revival, sets up the model of mouse S. aureus L-forms pneumonia.Lethal test gives 4 × 108CFUs S. aureus L-forms,
And histopathological examination gives 2 × 108CFUs S. aureus L-forms.
3.2 protective rates are tested
100,50 and 25mg/kg (100 μ l) naringenin is subcutaneously injected in 2h respectively after mouse inoculation S. aureus L-forms, the administration per 6h
Once.The physiological saline that control group gives 100 μ l, every group of 30 mouse are not administered.After Dosage Regimens Dosage, record respectively small
The death rate after mouse infection S. aureus L-forms 24h, 48h, 72h.
As a result show, after being handled through naringenin, significantly reduce the death rate (P ＜ 0.05) of mouse S. aureus L-forms pneumonia.Such as table
2.
Influence of the naringenin of table 2. to the mouse S. aureus L-forms pneumonia death rate
Claims (2)
1. application of the naringenin in treatment pneumonia medicine as caused by Staphylococcus aureus is prepared.
2. application according to claim 1, it is characterised in that the medicine includes pharmaceutically acceptable formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210231492.6A CN102872004B (en) | 2012-07-06 | 2012-07-06 | Application of the naringenin in treatment pneumonia medicine is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210231492.6A CN102872004B (en) | 2012-07-06 | 2012-07-06 | Application of the naringenin in treatment pneumonia medicine is prepared |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872004A CN102872004A (en) | 2013-01-16 |
| CN102872004B true CN102872004B (en) | 2017-07-14 |
Family
ID=47473678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210231492.6A Active CN102872004B (en) | 2012-07-06 | 2012-07-06 | Application of the naringenin in treatment pneumonia medicine is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872004B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107661316B (en) * | 2017-10-23 | 2020-05-15 | 太原理工大学 | Preparation method of polylactic acid coated naringenin and starch silver-loaded composite nano-particles |
| CN113773295B (en) * | 2021-09-26 | 2023-06-20 | 广东省科学院动物研究所 | Synthesis method of monosubstituted dihydro chromone and application of monosubstituted dihydro chromone in treatment of pulmonary inflammation such as COPD (chronic disease) |
| CN115300521B (en) * | 2022-09-20 | 2024-02-27 | 吉林大学 | Application of naringin in preparation of Sortase A sortase and PLY hemolysin inhibitor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1468602A (en) * | 2003-06-18 | 2004-01-21 | 中山大学 | Application of naringin in preparing medicine for supporting treatment of SARS |
-
2012
- 2012-07-06 CN CN201210231492.6A patent/CN102872004B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1468602A (en) * | 2003-06-18 | 2004-01-21 | 中山大学 | Application of naringin in preparing medicine for supporting treatment of SARS |
Non-Patent Citations (2)
| Title |
|---|
| 大鼠灌胃毛橘红醇提物血浆中柚皮苷、柚皮素及其代谢产物液质分析;孙国玲等;《中国中药杂志》;20100630;第35卷(第12期);1580-1585 * |
| 柚皮提取物对金黄色葡萄球菌抑制作用的初步研究;李春美等;《食品工业科技》;20041231(第5期);64-66 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872004A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308205A (en) | Pharmaceutical preparations of human rpe cells and uses thereof | |
| CA2104114C (en) | Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents | |
| KR20200032115A (en) | Compounds affecting the production of pigments for the treatment of bacterial infections and uses thereof | |
| US11628192B2 (en) | Bacteroides fragilis for relieving endotoxin infection and application thereof | |
| CN102872004B (en) | Application of the naringenin in treatment pneumonia medicine is prepared | |
| US20130034529A1 (en) | Natural compositions and methods of promoting wound healing | |
| IT202000003233A1 (en) | BACTERIAL STRAIN AND ITS MEDICAL USES | |
| CN103130865A (en) | Sophocarpidine, oxymatrine glycyrrhetinic acid double salt, and preparation method and use thereof | |
| CN104606218A (en) | Breast injection for treating cow lactation mastitis and preparation method thereof | |
| US11344625B2 (en) | Compositions having antifungal activity | |
| CN103191100A (en) | Application of puerarin in preparation of drug for treating pneumonia | |
| CN105412131A (en) | Application of verbascoside in preparation of pneumonia treatment drug | |
| CN102872003B (en) | Application of the apiolin in treatment pneumonia medicine is prepared | |
| Ekwenye et al. | Antibacterial effect of Phyllanthus niruri (Chanca Piedra) on three enteropathogens in man | |
| KR101156082B1 (en) | Composition for treating bovine mastitis | |
| CN102872005B (en) | Application of the glycyrrhizin in treatment pneumonia medicine is prepared | |
| CN111053764B (en) | Application of salvianolic acid A in preparation of medicine for treating methicillin-resistant staphylococcus aureus infectious pneumonia | |
| CN109464328A (en) | Plant type bacterio static itching-relieving liquid | |
| CN104224802B (en) | A kind of moxifloxacin hydrochloride auristilla and preparation method thereof | |
| CN104337797B (en) | A kind of preparation method of the composite drug-loaded tunica fibrosa of multiple medicine integrated-type | |
| CN102727509A (en) | Application of baicalin to preparation of medicament for treating pneumonia | |
| CN113041346A (en) | Bacterial toxin vaccine and application thereof in preventing bacterial infection | |
| CN107149611B (en) | Mongolian medicine rhinitis spray and preparation method thereof | |
| CN102429899A (en) | Application of baicalein to preparation of medicament for treating pneumonia | |
| CN102755311A (en) | Application of oroxylin A in preparing medicament for treating pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211222 Address after: 442100 No.2 Yingbin Avenue, Chengguan Town, Fang County, Shiyan City, Hubei Province Patentee after: HUBEI WUDANG ANIMAL PHARMACEUTICAL Co.,Ltd. Address before: 130012 No. 2699 Qianjin Street, Jilin, Changchun Patentee before: Jilin University |